Hua Zhu

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 38

Top Venues

Molecular pharmaceutics

ACS pharmacology & translational science

European journal of nuclear medicine and molecular imaging

Acta pharmacologica Sinica

Beijing Cancer Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Beijing Cancer Hospital Aug 01 2011

China

Associate Professor :: Department of nculear medicine

Publications

Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics 21 (4) (2024)
Jinping Tao, Ziqing Zeng, Chengxue He, Lin Meng, Wenyuan Zhou, Ya'nan Ren, Xiaopan Ma, Zilei Wang, Jiayue Liu, Dapeng Li, Qian Zhang, Chuanke Zhao, Zhi Yang, Hua Zhu
Construction and Preclinical Evaluation of 124 I/ 125 I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3. Molecular pharmaceutics (2024)
Chengxue He, Futao Liu, Jinping Tao, Zilei Wang, Jiayue Liu, Song Liu, Xiaoxia Xu, Liqiang Li, Feng Wang, Xianteng Yang, Hua Zhu, Zhi Yang
A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC. Molecular pharmaceutics (2024)
Jinping Tao, Ziqing Zeng, Chengxue He, Lin Meng, Wenyuan Zhou, Ya'nan Ren, Xiaopan Ma, Zilei Wang, Jiayue Liu, Dapeng Li, Qian Zhang, Chuanke Zhao, Zhi Yang, Hua Zhu
Construction and Preclinical Evaluation of 124 I/ 125 I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3. Molecular pharmaceutics 21 (2) (2024)
Jinping Tao, Ziqing Zeng, Chengxue He, Lin Meng, Wenyuan Zhou, Ya'nan Ren, Xiaopan Ma, Zilei Wang, Jiayue Liu, Dapeng Li, Qian Zhang, Chuanke Zhao, Zhi Yang, Hua Zhu
Construction and Preclinical Evaluation of 124 I/ 125 I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3. Molecular pharmaceutics 21 (2) (2024)
Chengxue He, Futao Liu, Jinping Tao, Zilei Wang, Jiayue Liu, Song Liu, Xiaoxia Xu, Liqiang Li, Feng Wang, Xianteng Yang, Hua Zhu, Zhi Yang
A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC. Molecular pharmaceutics 21 (7) (2024)
Jin Ding, Qian Zhang, Jinquan Jiang, Nina Zhou, Ziyu Yu, Zilei Wang, Xiangxi Meng, Lasya Daggumati, Teli Liu, Feng Wang, Zhihao Lu, Xing Yang, Zhi Yang, Hanwen Zhang, Daniel L J Thorek, Peng Du, Hua Zhu
Preclinical Evaluation and Pilot Clinical Study of 18 F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2. ACS pharmacology & translational science 7 (6) (2024)
Jin Ding, Qian Zhang, Jinquan Jiang, Nina Zhou, Ziyu Yu, Zilei Wang, Xiangxi Meng, Lasya Daggumati, Teli Liu, Feng Wang, Zhihao Lu, Xing Yang, Zhi Yang, Hanwen Zhang, Daniel L J Thorek, Peng Du, Hua Zhu
Preclinical Evaluation and Pilot Clinical Study of 18 F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2. ACS pharmacology & translational science 7 (6) (2024)
Yuan Yao, Yanan Ren, Xingguo Hou, Pei Wang, Jinyu Zhu, Song Liu, Xiaokun Ma, Teli Liu, Zhi Yang, Hua Zhu, Nan Li
Construction and preclinical evaluation of a 124 I-labelled bispecific antibody targeting PD-L1 and PD-L2. European journal of nuclear medicine and molecular imaging (2024)
Chengxue He, Futao Liu, Jinping Tao, Zilei Wang, Jiayue Liu, Song Liu, Xiaoxia Xu, Liqiang Li, Feng Wang, Xianteng Yang, Hua Zhu, Zhi Yang
A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC. Molecular pharmaceutics 21 (7) (2024)
Lixin Ding, Feng Wang, Zilei Wang, Yongxiang Pan, Teli Liu, Liansheng Cheng, Wenting Liu, Kuke Ding, Hua Zhu, Zhi Yang
Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells. Molecular pharmaceutics 21 (8) (2024)
Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics 21 (4) (2024)
Jinping Tao, Ziqing Zeng, Chengxue He, Lin Meng, Wenyuan Zhou, Ya'nan Ren, Xiaopan Ma, Zilei Wang, Jiayue Liu, Dapeng Li, Qian Zhang, Chuanke Zhao, Zhi Yang, Hua Zhu
Construction and Preclinical Evaluation of 124 I/ 125 I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3. Molecular pharmaceutics 21 (2) (2024)
Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics 21 (4) (2024)
Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics 21 (4) (2024)
Lixin Ding, Feng Wang, Zilei Wang, Yongxiang Pan, Teli Liu, Liansheng Cheng, Wenting Liu, Kuke Ding, Hua Zhu, Zhi Yang
Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells. Molecular pharmaceutics (2024)
Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics 21 (4) (2024)
Song Liu, Futao Liu, Xingguo Hou, Qian Zhang, Ya'nan Ren, Hua Zhu, Zhi Yang, Xiaoxia Xu
KRAS Mutation Detection with (2 S ,4 R )-4-[ 18 F]FGln for Noninvasive PDAC Diagnosis. Molecular pharmaceutics (2024)
Zilei Wang, Chuanke Zhao, Jin Ding, Yan Chen, Jiayue Liu, Xingguo Hou, XiangXing Kong, Bin Dong, Zhi Yang, Hua Zhu
Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular Imaging. ACS pharmacology & translational science 6 (12) (2023)
Lei Xia, Chengxue He, Yanhui Guo, Xiangxi Meng, Teli Liu, Xiaoxia Xu, Xiaoyi Guo, Feng Wang, Nan Li, Hua Zhu, Zhi Yang
Preparation and Application of a Bioorganic Nanoparticle-Enhanced PDL1-Targeted Small-Molecule Probe. ACS applied materials & interfaces (2023)
Pei Wang, Shuailiang Wang, Futao Liu, Ya'nan Ren, Qian Guo, Qian Zhang, XingGuo Hou, Yuan Yao, Hua Zhu, Zhi Yang
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. Molecular pharmaceutics 20 (2) (2023)
Pei Wang, Shuailiang Wang, Futao Liu, Ya'nan Ren, Qian Guo, Qian Zhang, XingGuo Hou, Yuan Yao, Hua Zhu, Zhi Yang
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. Molecular pharmaceutics (2023)
Xiao-Kun Ma, Te-Li Liu, Ya-Nan Ren, Xiao-Pan Ma, Yuan Yao, Xing-Guo Hou, Jin Ding, Feng Wang, Hai-Feng Huang, Hua Zhu, Zhi Yang
124 I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies. Acta pharmacologica Sinica (2023)
Pei Wang, Shuailiang Wang, Futao Liu, Ya'nan Ren, Qian Guo, Qian Zhang, XingGuo Hou, Yuan Yao, Hua Zhu, Zhi Yang
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. Molecular pharmaceutics 20 (2) (2023)
Ziqing Zeng, Liqiang Li, Jinping Tao, Jiayue Liu, Hongjun Li, Xueming Qian, Zhi Yang, Hua Zhu
[ 177 Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. European journal of nuclear medicine and molecular imaging (2023)
Pei Wang, Shuailiang Wang, Futao Liu, Ya'nan Ren, Qian Guo, Qian Zhang, XingGuo Hou, Yuan Yao, Hua Zhu, Zhi Yang
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. Molecular pharmaceutics 20 (2) (2023)
Dan Li, Feng Wang, Jinquan Jiang, Xingguo Hou, Jin Ding, Zilei Wang, Yan Chen, Teli Liu, Zhi Yang, Hua Zhu
Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging. Molecular pharmaceutics 19 (11) (2022)
Shuailiang Wang, Futao Liu, Pei Wang, Li Wen, Zilei Wang, Qian Guo, Hua Zhu, Zhi Yang
124 I Radiolabeled Basiliximab for CD25-Targeted Immuno-PET Imaging of Activated T Cells. Molecular pharmaceutics 19 (7) (2022)
Yuan Yao, Xingguo Hou, Song Liu, Teli Liu, Yanan Ren, Xiaokun Ma, Qian Zhang, Pei Wang, Qian Guo, Xiaopan Ma, Zhi Yang, Hua Zhu, Nan Li
Construction and Preclinical Evaluation of a 124/125 I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. Molecular pharmaceutics 20 (2) (2022)
Yuan Yao, Xingguo Hou, Song Liu, Teli Liu, Yanan Ren, Xiaokun Ma, Qian Zhang, Pei Wang, Qian Guo, Xiaopan Ma, Zhi Yang, Hua Zhu, Nan Li
Construction and Preclinical Evaluation of a 124/125 I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. Molecular pharmaceutics 20 (2) (2022)
Xingguo Hou, Feng Wang, Xiangxi Meng, Dan Li, Jin Ding, Yan Chen, Zilei Wang, Hua Zhu, Zhi Yang
Construction of a 124 I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors. Molecular pharmaceutics 19 (10) (2022)
Yuan Yao, Xingguo Hou, Song Liu, Teli Liu, Yanan Ren, Xiaokun Ma, Qian Zhang, Pei Wang, Qian Guo, Xiaopan Ma, Zhi Yang, Hua Zhu, Nan Li
Construction and Preclinical Evaluation of a 124/125 I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. Molecular pharmaceutics (2022)
Biao Hu, Tianyu Liu, Liqiang Li, Linqing Shi, Meinan Yao, Chenzhen Li, Xiaopan Ma, Hua Zhu, Bing Jia, Fan Wang
IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy. Bioconjugate chemistry 33 (7) (2022)
Yuan Yao, Xingguo Hou, Song Liu, Teli Liu, Yanan Ren, Xiaokun Ma, Qian Zhang, Pei Wang, Qian Guo, Xiaopan Ma, Zhi Yang, Hua Zhu, Nan Li
Construction and Preclinical Evaluation of a 124/125 I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. Molecular pharmaceutics 20 (2) (2022)
Chuanke Zhao, Zhuona Rong, Jin Ding, Lixin Wang, Bing Wang, Lei Ding, Lin Meng, Xiangxi Meng, Feng Wang, Zhi Yang, Chengchao Shou, Hua Zhu
Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery. Molecular pharmaceutics 19 (10) (2022)
Qian Zhang, Teli Liu, Jin Ding, Nina Zhou, Ziyi Yu, Yanan Ren, Xue Qin, Peng Du, Zhi Yang, Hua Zhu
Evaluation of 68 Ga- and 177 Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging. Molecular pharmaceutics 19 (11) (2022)
Lei Xia, Xiangxi Meng, Li Wen, Nina Zhou, Teli Liu, Xiaoxia Xu, Feng Wang, Zhen Cheng, Zhi Yang, Hua Zhu
A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer. Small (Weinheim an der Bergstrasse, Germany) 17 (21) (2021)
Xudong Wang, Feng Wang, Jintao Han, Zhi Yang, Hua Zhu, Gen Yang
Construction and Preclinical Evaluation of a 124/131I-Labeled Radiotracer for the Detection of Mesothelin-Overexpressing Cancer. Molecular pharmaceutics 17 (6) (2020)

Hua Zhu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hua Zhu